NASDAQ
156.17USD
+2.56 (+1.67%)
We have scored 58 news catalysts on Insulet Corp. (PODD) over the past 12 months. The biggest single-day move next to one of them came Jul 8, 2026, when PODD closed −2.5%: “Grabar Law Office Investigates Claims on Behalf of Photronics, Inc. (PLAB) Shareholders”. Coverage across the window leans negative (average ticker sentiment −0.48). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.8B
P/E
—
EPS
—
Beta
1.06
52W range
126.4-354.88
Day range
151.23–156.98
Open
152.08
Prev close
153.61
Volume
806.2K
Avg volume
1.6M
Dividend
0.00
IPO
2007-05-15
Analysts publish price targets on PODD, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
19 analyst price targets from $144 to $245
as of 2026-09-12
The market is 27% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Insulet Corp. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PODD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
The price sits at the very bottom of the published model range, 27% below the median target, meaning the market completely rejects the bull case and prices a steep deceleration from the 30.7% growth just delivered.
What the disagreement turns on
Whether the manufacturing defects and lawsuits permanently impair Insulet's market share and growth trajectory, or whether unit volume trends remain intact despite the overhang — a question that available unit volume data can help settle.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $132 on 2026-09-12 — the quote has since moved +18%, so read this as a record of what was priced in then, not now.
